

DAFTAR PUSTAKA

- Adamu, M. J., Qiang, L., Nyatega, C. O., Younis, A., Kawuwa, H. B., Jabire, A. H., & Saminu, S. (2023). Unraveling the pathophysiology of schizophrenia: insights from structural magnetic resonance imaging studies. *Frontiers in Psychiatry, 14*. <https://doi.org/10.3389/fpsy.2023.1188603>
- Addington, J., Liu, L., Buchy, L., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., Woods, S. W., Bearden, C. E., Mathalon, D. H., & McGlashan, T. H. (2015). North American Prodrome Longitudinal Study (NAPLS 2): The prodromal symptoms. *Journal of Nervous and Mental Disease, 203*(5), 328–335. <https://doi.org/10.1097/NMD.0000000000000290>
- Agee, E. R. (2015). The relationship between second-generation antipsychotic medication adherence and negative symptoms in first-episode schizophrenia. (*Doctoral Dissertation, Pepperdine University*).
- Ahern, G. P. (2011). 5-HT and the immune system. *Current Opinion in Pharmacology, 11*(1), 29–33. <https://doi.org/10.1016/J.COPH.2011.02.004>
- Al-Atram, A. A. (2018). A review of the bidirectional relationship between psychiatric disorders and diabetes mellitus. In *Neurosciences* (Vol. 23, Issue 2, pp. 91–96). Saudi Arabian Armed Forces Hospital. <https://doi.org/10.17712/nsj.2018.2.20170132>
- Alberich, S., Fernández-Sevillano, J., González-Ortega, I., Usall, J., Sáenz, M., González-Fraile, E., & González-Pinto, A. (2019). A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. *Psychiatry research, 280*, 112506.
- American Diabetes Association. (2014). Diagnosis and classification of diabetes mellitus. *Diabetes Care, 37*(SUPPL.1). <https://doi.org/10.2337/dc14-S081>
- American Diabetes Association. (2021). Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. *Diabetes Care, 44*, S15–S33. <https://doi.org/10.2337/dc21-S002>
- American Psychiatric Association, DSM-5 Task Force. (2013). *Diagnostic and statistical manual of mental disorders: DSM-5™* (5th ed.). American Psychiatric Publishing, Inc..

- Annamalai, A., Kosir, U., & Tek, C. (2017). Prevalence of obesity and diabetes in patients with schizophrenia. *World Journal of Diabetes*, 8(8), 390. <https://doi.org/10.4239/wjd.v8.i8.390>
- Annamalai, A., & Tek, C. (2015). An overview of diabetes management in schizophrenia patients: Office based strategies for primary care practitioners and endocrinologists. *International Journal of Endocrinology*, 2015. <https://doi.org/10.1155/2015/969182>
- Argaw, A. M., Hiwet, T. T., & Derse, B. B. (2019). Drug Therapy Problems and Determinants among Ambulatory Type 2 Diabetes Mellitus Patients: Pharmacists' Intervention in South-East Ethiopia. *Endocrinology & Metabolic Syndrome*, 08(04). <https://doi.org/10.35248/2161-1017.19.8.303>
- Arruda, A. L., Khandaker, G. M., Morris, A. P., Smith, G. D., Huckins, L. M., & Zeggini, E. (2024). Genomic insights into the comorbidity between type 2 diabetes and schizophrenia. *Schizophrenia*, 10(1). <https://doi.org/10.1038/s41537-024-00445-5>
- Arya, A., Sindhwani, G., & Kadian, R. (2018). Neurotransmitter and brain parts involved in schizophrenia. In *Asian Journal of Pharmaceutical and Clinical Research* (Vol. 11, Issue 6, pp. 4–11). Innovare Academics Sciences Pvt. Ltd. <https://doi.org/10.22159/ajpcr.2018.v11i6.24557>
- Banaj, N., Piras, F., Piras, F., Ciullo, V., Iorio, M., Battaglia, C., ... & Spalletta, G. (2018). Cognitive and psychopathology correlates of brain white/grey matter structure in severely psychotic schizophrenic inpatients. *Schizophrenia research: cognition*, 12, 29-36.
- Bae, S., Kim, M. C., Kim, J. Y., Cha, H. H., Lim, J. S., Jung, J., Kim, M. J., Oh, D. K., Lee, M. K., Choi, S. H., Sung, M., Hong, S. B., Chung, J. W., & Kim, S. H. (2020). Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled Comparison in 4 Patients. In *Annals of Internal Medicine* (Vol. 173, Issue 1, pp. W22–W23). American College of Physicians. <https://doi.org/10.7326/M20-1342>
- Banaj, N., Piras, F., Piras, F., Ciullo, V., Iorio, M., Battaglia, C., Pantoli, D., Ducci, G., & Spalletta, G. (2018). Cognitive and psychopathology correlates of brain white/grey matter structure in severely psychotic schizophrenic inpatients. *Schizophrenia Research: Cognition*, 12, 29–36. <https://doi.org/10.1016/J.SCOG.2018.02.001>
- Bora, E., Yücel, M., & Pantelis, C. (2009). Theory of mind impairment: A distinct trait-marker for schizophrenia spectrum disorders and bipolar disorder? In *Acta Psychiatrica Scandinavica* (Vol. 120, Issue 4, pp. 253–264). <https://doi.org/10.1111/j.1600-0447.2009.01414.x>
- Zhea Shafira Aqilla Sunardi, 2024
PENGARUH TERAPI KLOZAPIN DAN RISPERIDONE TERHADAP KADAR GLUKOSA DARAH PADA PASIEN RAWAT INAP SKIZOFRENIA KOMORBID DIABETES MELITUS TIPE 2 DI RSJ DR. H. MARZOEKI MAHDI BOGOR TAHUN 2023
 UPN Veteran Jakarta, Fakultas Kedokteran, S1 Farmasi
www.upnvj.ac.id-www.library.upnvj.ac.id-www.repository.upnvj.ac.id

- Bouwman, C., De Sonnevile, C., Mulder, C. L., & Hakkaart-van Roijen, L. (2015). Employment and the associated impact on quality of life in people diagnosed with schizophrenia. *Neuropsychiatric Disease and Treatment*, *11*, 2125–2142. <https://doi.org/10.2147/NDT.S83546>
- Boyda, H. N., Procyshyn, R. M., Tse, L., Wong, D., Pang, C. C., Honer, W. G., & Barr, A. M. (2012). Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. *Neuropharmacology*, *62*(3), 1391–1400. <https://doi.org/10.1016/J.NEUROPHARM.2011.02.019>
- Boyda, H. N., Tse, L., Procyshyn, R. M., Wong, D., Wu, T. K. Y., Pang, C. C., & Barr, A. M. (2010). A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, *34*(6), 945–954. <https://doi.org/10.1016/J.PNPBP.2010.04.024>
- Briggs, R. G., Khan, A. B., Chakraborty, A. R., Abraham, C. J., Anderson, C. D., Karas, P. J., Bonney, P. A., Palejwala, A. H., Conner, A. K., O'Donoghue, D. L., & Sughrue, M. E. (2020). Anatomy and White Matter Connections of the Superior Frontal Gyrus. *Clinical Anatomy*, *33*(6), 823–832. <https://doi.org/10.1002/ca.23523>
- Bughio, A. H., Ansari, S., Kumar, R., Sheikh, M. H., & Devrajani, T. (2021). Effect of atypical antipsychotics on blood glucose levels and HbA1c in patients of schizophrenia and bipolar disorder. *The Professional Medical Journal*, *28*(02), 158–164. <https://doi.org/10.29309/tpmj/2021.28.02.5189>
- Burghardt, K. J., Seyoum, B., Mallisho, A., Burghardt, P. R., Kowluru, R. A., & Yi, Z. (2018). Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, *83*, 55–63. <https://doi.org/10.1016/J.PNPBP.2018.01.004>
- Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M. (2021). Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. In *Pharmaceuticals* (Vol. 14, Issue 3). MDPI AG. <https://doi.org/10.3390/ph14030238>
- Chen, J., Huang, X. F., Shao, R., Chen, C., & Deng, C. (2017). Molecular mechanisms of antipsychotic drug-induced diabetes. In *Frontiers in Neuroscience* (Vol. 11, Issue NOV). Frontiers Media S.A. <https://doi.org/10.3389/fnins.2017.00643>
- Chen, Q., Beaty, R. E., & Qiu, J. (2020). Mapping the artistic brain: Common and distinct neural activations associated with musical, drawing, and literary creativity. *Human Brain Mapping*, *41*(12), 3403–3419. <https://doi.org/10.1002/hbm.25025>
- Zhea Shafira Aqilla Sunardi, 2024
PENGARUH TERAPI KLOZAPIN DAN RISPERIDONE TERHADAP KADAR GLUKOSA DARAH PADA PASIEN RAWAT INAP SKIZOFRENIA KOMORBID DIABETES MELITUS TIPE 2 DI RSJ DR. H. MARZOEKI MAHDI BOGOR TAHUN 2023
 UPN Veteran Jakarta, Fakultas Kedokteran, S1 Farmasi
www.upnvj.ac.id-www.library.upnvj.ac.id-www.repository.upnvj.ac.id

- Chung, Y., & Cannon, T. D. (2015). Brain imaging during the transition from psychosis prodrome to Schizophrenia. *Journal of Nervous and Mental Disease*, 203(5), 336–341. <https://doi.org/10.1097/NMD.0000000000000286>
- Citrome, L. . (2015). The ABC's of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. *Citrome, L. (2015). The ABC's of Dopamine Receptor Partial Agonists - Aripiprazole, Brexpiprazole and Cariprazine: The 15-Min Challenge to Sort These Agents out. International Journal of Clinical Practice*, 69(11), 1211–1220.
- Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. In *Neuropsychiatric Disease and Treatment* (Vol. 16, pp. 519–534). Dove Medical Press Ltd. <https://doi.org/10.2147/NDT.S225643>
- Cropley, V. L., Klauser, P., Lenroot, R. K., Bruggemann, J., Sundram, S., Bousman, C., Pereira, A., Di Biase, M. A., Weickert, T. W., Weickert, C. S., Pantelis, C., & Zalesky, A. (2017). Accelerated gray and white matter deterioration with age in schizophrenia. *American Journal of Psychiatry*, 174(3), 286–295. <https://doi.org/10.1176/appi.ajp.2016.16050610>
- Cullen, A. E., Holmes, S., Pollak, T. A., Blackman, G., Joyce, D. W., Kempton, M. J., Murray, R. M., McGuire, P., & Mondelli, V. (2019). Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis. *Biological Psychiatry*, 85(1), 35–48. <https://doi.org/10.1016/J.BIOPSYCH.2018.06.016>
- Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., & Samochowiec, J. (2021). The role of cytokines in the pathogenesis of schizophrenia. *Journal of Clinical Medicine*, 10(17). <https://doi.org/10.3390/jcm10173849>
- De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L., Martinotti, G., & Di Giannantonio, M. (2018). Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. *Therapeutic Advances in Drug Safety*, 9(5), 237–256. <https://doi.org/10.1177/2042098618756261>
- de Leon, J., Sandson, N. B., Cozza, K. L., & Leon, de. (2010). *The pharmacokinetics of paliperidone versus risperidone*. <https://doi.org/10.1176/appi.psy.51.1.80.PMID>
- DeLisi, L. E. , Szulc, K. U. , Bertisch, H. C. , Majcher, M. , & Brown, K. (2006). Understanding structural brain changes in schizophrenia. Dialogues in clinical neuroscience. *Dialogues in Clinical Neuroscience*.

- Demirci, Ö., Adar, İ., & Erbaş, O. (2023). E N T A L AND B A S I C An Overview of Antipsychotics: Mechanisms of Action. *Journal of Experimental and Basic Medical Sciences*, 4(1), 62–70. <https://doi.org/10.5606/jebms.2023.1047>
- Deng, S. W., Xu, Q., Jiang, W. L., Hong, B., Li, B. H., Sun, D. W., & Yang, H. B. (2023). Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *BMC Psychiatry*, 23(1). <https://doi.org/10.1186/s12888-023-05240-7>
- Dhua, A., Anand, S., Agarwala, S., & Bhatnagar, V. (2018). Comparison of anatomical landmarks and dimensions in a hypospadiac glans with those of a normal glans. *Journal of Indian Association of Pediatric Surgeons*, 23(3), 144. https://doi.org/10.4103/jiaps.jiaps_151_17
- Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2014). Pharmacotherapy: a pathophysiologic approach, ed. *Connecticut: Appleton and Lange*, 4, 141-142.
- DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. (2017). Pharmacotherapy A Pathophysiologic Approach, 10e. *Pharmacotherapy: A Pathophysiologic Approach. 10e. New York: McGraw-Hill Education*, 255-8.
- Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. In *BioMed Research International* (Vol. 2014). Hindawi Publishing Corporation. <https://doi.org/10.1155/2014/656370>
- Dobrodeeva, V. S., Abdyrahmanova, A. K., & Nasyrova, R. F. (2021). Personalized Psychiatry and Neurology Personalized approach to antipsychotic-induced weight gain prognosis. In *Personalized Psychiatry and Neurology* (Vol. 2021, Issue 1). www.JPPN.ru
- Dodsworth, T., Kim, D. D., Procyshyn, R. M., Ross, C. J., Honer, W. G., & Barr, A. M. (2018). A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. In *Child and Adolescent Psychiatry and Mental Health* (Vol. 12, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s13034-018-0243-2>
- Engler, C., Leo, M., Pfeifer, B., Juchum, M., Chen-Koenig, D., Poelzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., Middeldorf, K., Heindl, B., Gaenzer, H., Bode, G., Kirchmeyr, K., Ladner, G., Rieger, L., Koellensperger, U., Schwaiger, A., ... Ebenbichler, C. (2020). Long-term trends in the prescription of antidiabetic drugs: Real-world evidence from the Diabetes Registry Tyrol 2012-2018. *BMJ Open Diabetes Research and Care*, 8(1). <https://doi.org/10.1136/bmjdr-2020-001279>

Zhea Shafira Aqilla Sunardi, 2024

PENGARUH TERAPI KLOZAPIN DAN RISPERIDONE TERHADAP KADAR GLUKOSA DARAH PADA PASIEN RAWAT INAP SKIZOFRENIA KOMORBID DIABETES MELITUS TIPE 2 DI RSJ DR. H. MARZOEKI MAHDI BOGOR TAHUN 2023

UPN Veteran Jakarta, Fakultas Kedokteran, S1 Farmasi

[www.upnvj.ac.id-www.library.upnvj.ac.id-www.repository.upnvj.ac.id]

- Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009). Clozapine versus typical neuroleptic medication for schizophrenia. In *Cochrane Database of Systematic Reviews* (Issue 1). John Wiley and Sons Ltd. <https://doi.org/10.1002/14651858.CD000059.pub2>
- Farah, F. H. (2018). Schizophrenia: An Overview. In *Asian Journal of Pharmaceutics* (Vol. 12, Issue 2).
- Ferreira, V., Grajales, D., & Valverde, Á. M. (2020). Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, 1865(2), 158534. <https://doi.org/10.1016/J.BBALIP.2019.158534>
- Foroutan, N., Muratov, S., & Levine, M. (2016). Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. In *Clin Invest Med* • (Vol. 39, Issue 2).
- Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. In *International Journal of Molecular Sciences* (Vol. 21, Issue 17, pp. 1–34). MDPI AG. <https://doi.org/10.3390/ijms21176275>
- Ganga, S., Shareef, S., Tadvi, N., & Siddiqua, S. (2021). A comparative study of efficacy and adverse effects of monotherapy with combination therapy for oral anti-diabetics in diabetes mellitus type 2 patients. *National Journal of Physiology, Pharmacy and Pharmacology*, 11(6), 1. <https://doi.org/10.5455/njppp.2021.11.01021202126012021>
- Gannon, J. M., & Eack, S. M. (2017). Psychosocial treatment for psychotic disorders.
- Gautam, D., Han, S. J., Hamdan, F. F., Jeon, J., Li, B., Li, J. H., Cui, Y., Mears, D., Lu, H., Deng, C., Heard, T., & Wess, J. (2006). A critical role for β cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. *Cell Metabolism*, 3(6), 449–461. <https://doi.org/10.1016/J.CMET.2006.04.009>
- Getinet Ayano. (2016). Schizophrenia: A Concise Overview of Etiology, Epidemiology Diagnosis and Management: Review of literatures. *Research and Training Department, Amanuel Mental Specialized Hospital, Ethiopia*. www.austinpublishinggroup.com
- Giordano, G. M., Bucci, P., Mucci, A., Pezzella, P., & Galderisi, S. (2021). Gender Differences in Clinical and Psychosocial Features Among Persons With
- Zhea Shafira Aqilla Sunardi, 2024
PENGARUH TERAPI KLOZAPIN DAN RISPERIDONE TERHADAP KADAR GLUKOSA DARAH PADA PASIEN RAWAT INAP SKIZOFRENIA KOMORBID DIABETES MELITUS TIPE 2 DI RSJ DR. H. MARZOEKI MAHDI BOGOR TAHUN 2023
 UPN Veteran Jakarta, Fakultas Kedokteran, S1 Farmasi
www.upnvj.ac.id-www.library.upnvj.ac.id-www.repository.upnvj.ac.id

- Schizophrenia: A Mini Review. In *Frontiers in Psychiatry* (Vol. 12). Frontiers Media S.A. <https://doi.org/10.3389/fpsy.2021.789179>
- Gordon, J., McEwan, P., Idris, I., Evans, M., & Puelles, J. (2018). Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: A UK clinical practice database study. *BMJ Open Diabetes Research and Care*, 6(1). <https://doi.org/10.1136/bmjdr-2018-000512>
- Goyal, R. , Singhal, M. , Jialal, I. , & Castano, M. (2023). *Type 2 Diabetes (Nursing)*. In *StatPearls Publishing*. <https://www.statpearls.com/keywords/articlelist/>
- Grinchii, D., & Dremencov, E. (2020). Mechanism of action of atypical antipsychotic drugs in mood disorders. In *International Journal of Molecular Sciences* (Vol. 21, Issue 24, pp. 1–15). MDPI AG. <https://doi.org/10.3390/ijms21249532>
- Hahn, M., Chintoh, A., Giacca, A., Xu, L., Lam, L., Mann, S., Fletcher, P., Guenette, M., Cohn, T., Wolever, T., Arenovich, T., & Remington, G. (2011). Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: An animal model. *Schizophrenia Research*, 131(1–3), 90–95. <https://doi.org/10.1016/J.SCHRES.2011.06.004>
- Haidary, H. A., & Padhy, R. K. (2023). Clozapine.[Updated 2021 Dec 6].
- Henderson, D. C., Cagliero, E., Gray Rima Nasrallah, C. A., Doug Hayden, B. L., David Schoenfeld, M. A., & Goff, D. C. (2000). Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study. In *Am J Psychiatry* (Vol. 157, Issue 6).
- Hjorth, P., Espensen, C. H., Madsen, N. J., Viuff, A. G., & Munk-Jørgensen, P. (2018). Reducing the Risk of Type 2 Diabetes in Nonselected Outpatients with Schizophrenia: A 30-Month Program. *Journal of Psychiatric Practice*, 24(1), 21–31. <https://doi.org/10.1097/PRA.0000000000000278>
- Hjorthøj, C., Posselt, C. M., & Nordentoft, M. (2021). Development over time of the population-attributable risk fraction for cannabis use disorder in schizophrenia in Denmark. *JAMA psychiatry*, 78(9), 1013-1019.
- Holm, M., Taipale, H., Tanskanen, A., Tiihonen, J., & Mitterdorfer-Rutz, E. (2021). Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers. *Acta Psychiatrica Scandinavica*, 143(1), 61–71. <https://doi.org/10.1111/acps.13254>

- Holt, R. I. G. (2019). Association Between Antipsychotic Medication Use and Diabetes. In *Current Diabetes Reports* (Vol. 19, Issue 10). Current Medicine Group LLC 1. <https://doi.org/10.1007/s11892-019-1220-8>
- Hou, L., Zhao, T., Liu, Y., & Zhang, Y. (2015). Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A Meta-Analysis. *Experimental and Therapeutic Medicine*, 9(4), 1528–1536. <https://doi.org/10.3892/etm.2015.2277>
- Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *The Lancet*, 394(10202), 939–951. [https://doi.org/10.1016/S0140-6736\(19\)31135-3](https://doi.org/10.1016/S0140-6736(19)31135-3)
- Hutton, P., & Taylor, P. J. (2014). Cognitive behavioural therapy for psychosis prevention: A systematic review and meta-analysis. In *Psychological Medicine* (Vol. 44, Issue 3, pp. 449–468). <https://doi.org/10.1017/S0033291713000354>
- Idaiani, S., Yunita, I., Tjandrarini, D. H., Indrawati, L., Darmayanti, I., Kusumawardani, N., & Mubasyiroh, R. (2019). Prevalensi Psikosis di Indonesia berdasarkan Riset Kesehatan Dasar 2018. *Jurnal Penelitian Dan Pengembangan Pelayanan Kesehatan*, 9–16. <https://doi.org/10.22435/jpppk.v3i1.1882>
- Idrus, F., Singara, T., Sunarto, D., Syamsuddin, S., & Lisal, S. T. (2021). Abnormalities in glucose blood level during antipsychotic treatment in schizophrenia patients. *Open Access Macedonian Journal of Medical Sciences*, 9(T3), 340–344. <https://doi.org/10.3889/oamjms.2021.6294>
- Ince, S. Ç., Günüşen, N. P., Özerdem, A., & Özişik, S. (2017). Diabetes self-care views of individuals with severe mental illness and comorbid type 2 diabetes and of those only with type 2 diabetes. *Archives of Psychiatric Nursing*, 31(4), 386–393.
- Indonesia, P. E. (2015). Pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. *Pb. Perkeni*.
- Indonesia, P. E. (2021). Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. *PB PERKENI. Jakarta: PB PERKENI*.
- International Diabetes Federation. (2015). *IDF diabetes atlas*. International Diabetes Federation.

- Isnenia, I. (2022). Pattern of Antipsychotics in Schizophrenia Outpatients at Lampung Province Mental Hospital. *Jurnal Ilmiah Medicamento*, 8(1), 31–39. <https://doi.org/10.36733/medicamento.v8i1.3201>
- Institute of Health Metrics and Evaluation. (2021). Global health data exchange (GHDx). [VizHub - GBD Results \(healthdata.org\)](https://vizhub.healthdata.org/gbd-results/)
- Johnson, E. L., Feldman, H., Butts, A., Billy, C. D. R., Dugan, J., Leal, S., Rhinehart, A. S., Shubrook, J. H., Trujillo, J., Neumiller, J. J., Cannon, C., de Boer, I., Crandall, J., D'Alessio, D., de Groot, M., Fradkin, J., Kreider, K., Maahs, D., Maruthur, N., ... Uelmen, S. (2019). Standards of medical care in diabetes—2019 abridged for primary care providers. *Clinical Diabetes*, 37(1), 11–34. <https://doi.org/10.2337/cd18-0105>
- Kalra, S. , Das, A. K. , Baruah, M. P. , Unnikrishnan, A. G. , Dasgupta, A. , Shah, P. , & Czupryniak, L. (2019). *Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group*.
- Kartika, Y. , Saida, S. A. , & Nola, S. (2020). Gambaran Kadar Gula Darah Pasien Skizofrenia Tipe Paranoid yang Menggunakan Klozapin Di BLUD Rumah Sakit Jiwa Aceh. *Kandidat: Jurnal Riset Dan Inovasi Pendidikan*, 2(1), 108-115.
- Kemenkes RI. (2014). Panduan Praktik Klinis Bagi Dokter di Fasilitas Pelayanan Primer Edisi II, *Menteri Kesehatan Republik Indonesia*.
- Kemenkes, R. I. (2014). Profil kesehatan indonesia. *Jakarta: Kementerian Kesehatan Republik Indonesia*.
- Kirrane, A., Majumdar, B., & Richman, A. (2018). Clozapine use in old age psychiatry. *BJPsych Advances*, 24(3), 204–211. <https://doi.org/10.1192/bja.2017.26>
- Klemetilä, J. P., Kampman, O., Seppälä, N., Viikki, M., Hämäläinen, M., Moilanen, E., Mononen, N., Lehtimäki, T., & Leinonen, E. (2015). Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. *European Psychiatry*, 30(2), 296–302. <https://doi.org/10.1016/J.EURPSY.2014.08.006>
- Ko, S. H., Hur, K. Y., Rhee, S. Y., Kim, N. H., Moon, M. K., Park, S. O., Lee, B. W., Kim, H. J., Choi, K. M., & Kim, J. H. (2017). Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. *The Korean Journal of Internal Medicine*, 32(6), 947–958. <https://doi.org/10.3904/kjim.2017.298>
- Kochi, K., Sato, I., Nishiyama, C., Tanaka-Mizuno, S., Doi, Y., Arai, M., Fujii, Y., Matsunaga, T., Ogawa, Y., Furukawa, T. A., & Kawakami, K. (2017). Trends in
- Zhea Shafira Aqilla Sunardi, 2024
PENGARUH TERAPI KLOZAPIN DAN RISPERIDONE TERHADAP KADAR GLUKOSA DARAH PADA PASIEN RAWAT INAP SKIZOFRENIA KOMORBID DIABETES MELITUS TIPE 2 DI RSJ DR. H. MARZOEKI MAHDI BOGOR TAHUN 2023
 UPN Veteran Jakarta, Fakultas Kedokteran, S1 Farmasi
www.upnvj.ac.id-www.library.upnvj.ac.id-www.repository.upnvj.ac.id

- antipsychotic prescriptions for Japanese outpatients during 2006–2012: a descriptive epidemiological study. *Pharmacoepidemiology and Drug Safety*, 26(6), 642–656. <https://doi.org/10.1002/pds.4187>
- Kowalchuk, C., Castellani, L. N., Chintoh, A., Remington, G., Giacca, A., & Hahn, M. K. (2019). Antipsychotics and glucose metabolism: how brain and body collide. *Am J Physiol Endocrinol Metab*, 316, 1–15. <https://doi.org/10.1152/ajpendo.00164.2018>.-Since
- Kruse, A. O., & Bustillo, J. R. (2022). Glutamatergic dysfunction in Schizophrenia. In *Translational Psychiatry* (Vol. 12, Issue 1). Springer Nature. <https://doi.org/10.1038/s41398-022-02253-w>
- Kurdyak, P., Vigod, S., Duchon, R., Jacob, B., Stukel, T., & Kiran, T. (2017). Diabetes quality of care and outcomes: Comparison of individuals with and without schizophrenia. *General Hospital Psychiatry*, 46, 7–13. <https://doi.org/10.1016/J.GENHOSPPSYCH.2017.02.001>
- Kurniawan, A. H. , Elisya, Y. , & Irfan, M. (2020). Studi Literatur: Rasionalitas Penggunaan Antipsikotik Pada Pasien Gangguan Kejiwaan Skizofrenia. *Jurnal Insan Farmasi Indonesia*, 3(2), 199-208.
- Kurtz, M. M., Moberg, P. J., Gur, R. C., & Gur, R. E. (1999). Style file version March 18. In *Neuropsychology Review* (Vol. 11, Issue 4).
- Kusumi, I., Boku, S., & Takahashi, Y. (2015). Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. In *Psychiatry and Clinical Neurosciences* (Vol. 69, Issue 5, pp. 243–258). <https://doi.org/10.1111/pcn.12242>
- Lehman, A. F., Jeffrey Lieberman, C. A., Lisa Dixon, V.-C. B., Thomas McGlashan, M. H., Miller, A. L., Perkins, D. O., Julie Kreyenbuhl, M., McIntyre, J. S., Anzia, D. J., Cook, I. A., Finnerty, M. T., Johnson, B. R., Nininger, J. E., Summergrad, P., Woods, S. M., Yager, J., Pyles, R., Ann Barnovitz, M., Hafter Gray, S., ... Regier, D. A. (2010). *PRACTICE GUIDELINE FOR THE Treatment of Patients With Schizophrenia Second Edition WORK GROUP ON SCHIZOPHRENIA AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES AREA AND COMPONENT LIAISONS STAFF Treatment of Patients With Schizophrenia 3 CONTENTS*. <http://www.appi.org/CustomerService/Pages/Permissions.aspx>.<http://www.appi.org/CustomerService/Pages/Permissions.aspx>.
- Lester, H. E., Tritter, J. Q., & Sorohan, H. (2005). Patients' and health professionals' views on primary care for people with serious mental illness: Focus group study.

British Medical Journal, 330(7500), 1122–1126.
<https://doi.org/10.1136/bmj.38440.418426.8F>

- Lipscombe, L. L., Austin, P. C., Alessi-Severini, S., Blackburn, D. F., Blais, L., Bresee, L., Fillion, K. B., Kawasumi, Y., Kurdyak, P., Platt, R. W., Tamim, H., & Paterson, J. M. (2014). Atypical antipsychotics and hyperglycemic emergencies: Multicentre, retrospective cohort study of administrative data. *Schizophrenia Research*, 154(1–3), 54–60. <https://doi.org/10.1016/J.SCHRES.2014.01.043>
- Maletic, V., Eramo, A., Gwin, K., Offord, S. J., & Duffy, R. A. (2017). The role of norepinephrine and its α -adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: A systematic Review. In *Frontiers in Psychiatry* (Vol. 8, Issue MAR). Frontiers Research Foundation. <https://doi.org/10.3389/fpsy.2017.00042>
- Maqbool, M., Amin Dar, M., Gani, I., Rasool, S., & Dar, A. (2019). Risperidone in Schizophrenia: An Overview. In *Acta Scientific Pharmaceutical Sciences* (Vol. 3). <https://www.researchgate.net/publication/332861797>
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016). Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. In *Annals of Internal Medicine* (Vol. 164, Issue 11, pp. 740–751). American College of Physicians. <https://doi.org/10.7326/M15-2650>
- Maslim, R. (2013). Diagnosis gangguan jiwa. *Jakarta: Nuh Jaya*.
- McGrath, J. J., Saha, S., Al-Hamzawi, A., Alonso, J., Bromet, E. J., Bruffaerts, R., Caldas-De-Almeida, J. M., Chiu, W. T., De Jonge, P., Fayyad, J., Florescu, S., Gureje, O., Haro, J. M., Hu, C., Kovess-Masfety, V., Lepine, J. P., Lim, C. C. W., Mora, M. E. M., Navarro-Mateu, F., ... Kessler, R. C. (2015). Psychotic experiences in the general population: A cross-national analysis based on 31 261 respondents from 18 countries. *JAMA Psychiatry*, 72(7), 697–705. <https://doi.org/10.1001/jamapsychiatry.2015.0575>
- Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. (2013). Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? a comparative meta-analysis of first episode, untreated and treated patients. *Schizophrenia Bulletin*, 39(2), 295–305. <https://doi.org/10.1093/schbul/sbs082>
- Misnadiarly, A. S. (2006). Diabetes Mellitus: Mengenali Gejala, Menanggulangi, dan Mencegah Komplikasi.

Zhea Shafira Aqilla Sunardi, 2024

PENGARUH TERAPI KLOZAPIN DAN RISPERIDONE TERHADAP KADAR GLUKOSA DARAH PADA PASIEN RAWAT INAP SKIZOFRENIA KOMORBID DIABETES MELITUS TIPE 2 DI RSJ DR. H. MARZOEKI MAHDI BOGOR TAHUN 2023

UPN Veteran Jakarta, Fakultas Kedokteran, S1 Farmasi

[www.upnvj.ac.id-www.library.upnvj.ac.id-www.repository.upnvj.ac.id]

- Monasterio, E. , & McKean, A. (2011). Prescribing atypical antipsychotics in general practice. *Best Practice Journal*, 40, 14-23.
- Mori, N., McEvoy, J. P., & Miller, B. J. (2015). Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. *Schizophrenia Research*, 169(1–3), 30–35. <https://doi.org/10.1016/J.SCHRES.2015.10.001>
- Nanda, O. D., Wiryanto, B., & Triyono, E. A. (2018). Hubungan kepatuhan minum obat anti diabetik dengan regulasi kadar gula darah pada pasien perempuan diabetes mellitus. *Amerta Nutrition*, 2(4), 340-348.
- Nelson, M. T., Seal, M. L., Pantelis, C., & Phillips, L. J. (2013). Evidence of a dimensional relationship between schizotypy and schizophrenia: a systematic review. *Neuroscience & Biobehavioral Reviews*, 37(3), 317-327.
- Newcomer, J. W., Nasrallah, H. A., & Loebel, A. D. (2004). The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. *Journal of clinical Psychopharmacology*, 24(5), S1-S6.
- Niemann, K., Hammers, A., Coenen, V. A., Thron, A., & Klosterkötter, J. (2000). Evidence of a smaller left hippocampus and left temporal horn in both patients with first episode schizophrenia and normal control subjects. *Psychiatry research*, 99(2), 93–110. [https://doi.org/10.1016/s0925-4927\(00\)00059-7](https://doi.org/10.1016/s0925-4927(00)00059-7).
- Nieto-Vazquez, I., Fernández-Veledo, S., Krämer, D. K., Vila-Bedmar, R., Garcia-Guerra, L., & Lorenzo, M. (2008). Insulin resistance associated to obesity: the link TNF-alpha. *Archives of physiology and biochemistry*, 114(3), 183-194.
- Nishanth, T., Maheswari, C. U., Lakshmi, R. S., Sri, D., Goud, P., & Tabassum, K. (2018). A study to compare efficacy of metformin-glimepiride versus metformin-teneligliptin in type II diabetic patients. *Int J Pharm Sci Res*, 9(12), 5258-64.
- Pagsberg, A. K. (2013). Schizophrenia spectrum and other psychotic disorders. *European child & adolescent psychiatry*, 22, 3-9.
- Pantuzza, L. L., Ceccato, M. D. G. B., Silveira, M. R., Junqueira, L. M. R., & Reis, A. M. M. (2017). Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. *European journal of clinical pharmacology*, 73, 1475-1489.
- Parellada, E. (2007). Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. *Psychopharmacology Bulletin*, 40(2), 82-100.

- Patel, K. R. , Cherian, J. , Gohil, K. , & Atkinson, D. (2014). *Schizophrenia: overview and treatment options. Pharmacy and Therapeutics.*
- Peuskens, J. (1995). Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. *The British Journal of Psychiatry, 166*(6), 712-726.
- Pina-Camacho, L., Del Rey-Mejías, Á., Janssen, J., Bioque, M., González-Pinto, A., Arango, C., ... & PEPs Group. (2016). Age at first episode modulates diagnosis-related structural brain abnormalities in psychosis. *Schizophrenia bulletin, 42*(2), 344-357.
- Popi Latifah Bawean, & Isra Thristy. (2023). PERBANDINGAN PENGGUNAAN ANTIPSIKOTIK ATIPIKAL TUNGGAL DAN KOMBINASI TERHADAP KADAR GLUKOSA DARAH PADA PASIEN SKIZOFRENIA. *UNIVERSITAS MUHAMMADIYAH SUMATERA UTARA.*
- Poyraz, C. A., Özdemir, A., Sağlam, N. G. U., Turan, Ş., Poyraz, B. Ç., Tomruk, N., & Duran, A. (2016). Rapid klozapin titration in patients with treatment refractory schizophrenia. *Psychiatric Quarterly, 87*, 315-322.
- Prabawa, I. P. A. G., Witari, P. K., & Ariawan, I. W. Y. (2019). Gambaran sindrom metabolik pada pasien gangguan jiwa yang dirawat di rumah sakit jiwa provinsi Bali. *Intisari Sains Medis, 10*(2).
- Pridan, S., Swartz, M., Baruch, Y., Tadger, S., Plopski, I., & Barak, Y. (2015). Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. *International Psychogeriatrics, 27*(1), 131-134.
- Puangpetch, A., Srisawasdi, P., Unaharassamee, W., Jiratjintana, N., Vanavanan, S., Punprasit, S., ... & Kroll, M. H. (2019). Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone-or clozapine-induced hyperglycemia. *Pharmacogenomics and Personalized Medicine, 155-166.*
- Raja, M. (2009). Pharmacotherapy update: risperidone in the treatment of schizophrenia. *Clinical Medicine. Therapeutics, 1*, CMT-S1123.
- Rajkumar, A. P., Horsdal, H. T., Wimberley, T., Cohen, D., Mors, O., Børghlum, A. D., & Gasse, C. (2017). Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. *American Journal of Psychiatry, 174*(7), 686-694.
- Ratnasari, P. M. D., Ardeliani, I. G. A. I., Yuliawati, A. N., & Kurnianta, P. D. M. (2023). Association Between Antidiabetic Pattern with Medication Adherence in Type
- Zhea Shafira Aqilla Sunardi, 2024
PENGARUH TERAPI KLOZAPIN DAN RISPERIDONE TERHADAP KADAR GLUKOSA DARAH PADA PASIEN RAWAT INAP SKIZOFRENIA KOMORBID DIABETES MELITUS TIPE 2 DI RSJ DR. H. MARZOEKI MAHDI BOGOR TAHUN 2023
 UPN Veteran Jakarta, Fakultas Kedokteran, S1 Farmasi
www.upnvj.ac.id-www.library.upnvj.ac.id-www.repository.upnvj.ac.id

- 2 Diabetes Patients at Buleleng Hospital. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy)(e-Journal)*, 9(2), 132-146.
- Rethink (2009) Health inequalities are killing people with mental illness. Available at: <http://bit.ly/15A3ifl> (accessed 07.03.13)
- Riddle, M. C. (2017). Modern sulfonylureas: dangerous or wrongly accused?. *Diabetes Care*, 40(5), 629-631.
- Robert, A. S. (2022). An Overview on Schizophrenia. *Journal of Neurol Neurophy*, 13(1), 572. Department of Neuroscience, Harvard University, Cambridge, United States.
- Robison, A. J., Thakkar, K. N., & Diwadkar, V. A. (2020). Cognition and reward circuits in schizophrenia: synergistic, not separate. *Biological Psychiatry*, 87(3), 204-214.
- Rojo, L. E., Gaspar, P. A., Silva, H., Risco, L., Arena, P., Cubillos-Robles, K., & Jara, B. (2015). Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. *Pharmacological research*, 101, 74-85.
- Ruiz-Iriondo, M., Salaberria, K., & Echeburúa, E. (2013). Schizophrenia: analysis and psychological treatment according to the clinical staging. *Actas espanolas de psiquiatria*, 41(1).
- Sadock, B. J. (2015). *Kaplan & Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry* (Vol. 2015, pp. 648-655). Philadelphia, PA: Wolters Kluwer.
- Sahay, R. K., Mittal, V., Gopal, G. R., Kota, S., Goyal, G., Abhyankar, M., & Revenkar, S. (2020). Glimepiride and metformin combinations in diabetes comorbidities and complications: real-world evidence. *Cureus*, 12(9).
- Sanchez-Rangel, E., & Inzucchi, S. E. (2017). Metformin: clinical use in type 2 diabetes. *Diabetologia*, 60, 1586-1593.
- Sappo, N. B., Rahmawati, D., & Ramadhan, A. M. (2017, November). Karakteristik dan pola penggunaan obat anti diabetik pada pasien diabetes melitus tipe 2 di rsud abdul wahab sjarahranie. In *Proceeding of Mulawarman Pharmaceuticals Conferences* (Vol. 6, pp. 41-47).
- Sapra, A., & Bhandari, P. (2023). Diabetes. In *StatPearls*. StatPearls Publishing.

- Sarhan, A. L., Obaid, W., Sabouba, M., & Mahamid, F. (2023). Marriage Experience Among Patients with Schizophrenia: A Qualitative Narrative Study. *Journal of Psychosocial Rehabilitation and Mental Health*, *10*(1), 119-127.
- Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F., Gavin III, J. R., & Aguilar, R. B. (2016). The time is right for a new classification system for diabetes: rationale and implications of the β -cell–centric classification schema. *Diabetes care*, *39*(2), 179-186.
- Seeman, M. V. (2019). Does gender influence outcome in schizophrenia?. *Psychiatric Quarterly*, *90*(1), 173-184.
- Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016). Significance of HbA1c test in diagnosis and prognosis of diabetic patients. *Biomarker insights*, *11*, BMI-S38440.
- Shi, T., Papay, R. S., & Perez, D. M. (2016). α 1A-Adrenergic receptor prevents cardiac ischemic damage through PKC δ /GLUT1/4-mediated glucose uptake. *Journal of Receptors and Signal Transduction*, *36*(3), 261-270.
- Singh, V. P. (2016). An overview on anti diabetic drugs and development. *Sci Technol J*, *4*(2), 113-123.
- Solis-Herrera, C., Triplitt, C., Reasner, C., DeFronzo, R. A., & Cersosimo, E. (2018). Classification of Diabetes Mellitus. In K. R. Feingold (Eds.) et. al., *Endotext*. MDText.com, Inc.
- Stahl, S. M. (2013). *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications*. Cambridge University Press.
- Stahl, S. M. (2021). *Stahl's essential psychopharmacology: neuroscientific basis and practical applications*. Cambridge university press.
- Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current concepts and treatments of schizophrenia. *Molecules*, *23*(8), 2087.
- Stojkovic, M., Radmanovic, B., Jovanovic, M., Janjic, V., Muric, N., & Ristic, D. I. (2022). Risperidone induced hyperprolactinemia: from basic to clinical studies. *Frontiers in Psychiatry*, *13*, 874705.
- Stubbs, B., Vancampfort, D., De Hert, M., & Mitchell, A. J. (2015). The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. *Acta Psychiatrica Scandinavica*, *132*(2), 144-157.

- Sugiyono, P. D. (2019). Metode Penelitian Pendidikan (Kuantitatif, Kualitatif, Kombinasi, R&d dan Penelitian Pendidikan). *Metode Penelitian Pendidikan*, 67.
- Sullivan, L. C., Clarke, W. P., & Berg, K. A. (2015). Atypical Antipsychotics and Inverse Agonism at 5-HT₂ Receptors HHS Public Access. In *Curr Pharm Des* (Vol. 21, Issue 26).
- Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., ... & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes research and clinical practice*, 183, 109119.
- Syarif, A., Ascobat, P., Setiabudi, R., & lainnya. (2012). *Farmakologi dan Terapi* (Edisi 5). Badan Penerbit FKUI.
- Sylvester, E., Yi, W., Han, M., & Deng, C. (2020). Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. *Pharmacology Biochemistry and Behavior*, 199, 173064.
- Tandon, R., & Jibson, M. D. (2002). Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. *Annals of clinical psychiatry*, 14, 123-129.
- Tarwoto, W., Taufiq, I., & Mulyati, L. (2016). Keperawatan medikal bedah gangguan sistem endokrin. Jakarta: CV. *Trans Info Media*.
- Temmingh, H. S., Williams, T., Siegfried, N., & Stein, D. J. (2018). Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. *Cochrane Database of Systematic Reviews*, (1).
- Terevnikov, V., Joffe, G., & Stenberg, J. H. (2015). Randomized controlled trials of add-on antidepressants in schizophrenia. *International Journal of Neuropsychopharmacology*, 18(9), pyv049.
- Thuswaldner, J., & Lau, T. (2021). Older Adults with First-Onset Schizophrenia: An Under-Recognized and Under-Served Patient Population. *Clinical Schizophrenia & Related Psychoses*, 15(1).
- Tiihonen, J., Tanskanen, A., Bell, J. S., Dawson, J. L., Kataja, V., & Taipale, H. (2022). Long-term treatment with klozapin and other antipsychotic drugs and the risk of hematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. *The Lancet Psychiatry*, 9(5), 353-362.

- Turk, T., Alkhatib, M., Abbas, G., Jawish, M. K., Alshar, O. M. H., Abou Alchamat, H., & Essali, A. (2017). Risperidone (oral forms) for people with schizophrenia. *The Cochrane Database of Systematic Reviews*, 2017(10).
- Ulcickas Yood, M., DeLorenze, G. N., Quesenberry, C. P., Oliveria, S. A., Tsai, A. L., Kim, E., ... & L'Italien, G. J. (2011). Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?. *BMC psychiatry*, 11, 1-6.
- Unger, R. H., & Orci, L. (2010). Paracrinology of islets and the paracrinopathy of diabetes. *Proceedings of the national academy of Sciences*, 107(37), 16009-16012.
- Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., ... & Stubbs, B. (2016). Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. *World Psychiatry*, 15(2), 166-174.
- Velligan, D. I., & Rao, S. (2023). Schizophrenia: Salient Symptoms and Pathophysiology. *The Journal of clinical psychiatry*, 84(1), 45113.
- Vicchi, F. L., Luque, G. M., Brie, B., Nogueira, J. P., Tornadu, I. G., & Becu-Villalobos, D. (2016). Dopaminergic drugs in type 2 diabetes and glucose homeostasis. *Pharmacological research*, 109, 74-80.
- Wagner, E., Siafis, S., Fernando, P., Falkai, P., Honer, W. G., Röh, A., ... & Hasan, A. (2021). Efficacy and safety of klozapin in psychotic disorders—a systematic quantitative meta-review. *Translational psychiatry*, 11(1), 487.
- Wani, R. A., Dar, M. A., Margoob, M. A., Rather, Y. H., Haq, I., & Shah, M. S. (2015). Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. *Journal of neurosciences in rural practice*, 6(01), 017-022.
- Ward, M., & Druss, B. (2015). The epidemiology of diabetes in psychotic disorders. *The Lancet Psychiatry*, 2(5), 431-451
- Warnez, S., & Alessi-Severini, S. (2014). Clozapine: a review of clinical practice guidelines and prescribing trends. *BMC psychiatry*, 14, 1-5.
- Wesley, E. W., Kadra-Scalzo, G., Pritchard, M., Shetty, H., Broadbent, M., Segev, A., ... & de Freitas, D. F. (2021). Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. *Schizophrenia Research*, 232, 68-76.

- Wexler, D. J. (2021). Initial management of hyperglycemia in adults with type 2 diabetes mellitus. *UpToDate, Waltham, MA*.
- Wilianto, Y. R. (2019). Side Effects of Antipsychotics on Schizophrenia Patients: A Literature Review. *Side Effects of Antipsychotics on Schizophrenia Patients: A Literature Review, 4(2)*, 35-44.
- World Health Organization. (2022). *Mental health atlas 2020: review of the Eastern Mediterranean Region*.
- Wu, C. S., Lai, M. S., & Gau, S. S. F. (2015). Complications and mortality in patients with schizophrenia and diabetes: population-based cohort study. *The British journal of psychiatry, 207(5)*, 450-457.
- Xia, L., Li, W. Z., Liu, H. Z., Hao, R., & Zhang, X. Y. (2018). Olanzapine versus risperidone in children and adolescents with psychosis: a meta-analysis of randomized controlled trials. *Journal of child and adolescent psychopharmacology, 28(4)*, 244-251.
- Xiu, L., Lin, M., Liu, W., Kong, D., Liu, Z., Zhang, Y., ... & Ding, Y. (2015). Association of DRD3, COMT, and SLC6A4 gene polymorphisms with Type 2 diabetes in Southern Chinese: a hospital-based case-control study. *Diabetes technology & therapeutics, 17(8)*, 580-586.
- Xu, M. Y., & Wong, A. H. (2018). GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. *Acta Pharmacologica Sinica, 39(5)*, 733-753.
- Yi, W., She, S., Zhang, J., Wu, H., Zheng, Y., & Ning, Y. (2020). Clozapine use in patients with early-stage schizophrenia in a Chinese psychiatric hospital. *Neuropsychiatric Disease and Treatment, 2827-2836*.
- Young, S. L., Taylor, M., & Lawrie, S. M. (2015). "First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects. *Journal of Psychopharmacology, 29(4)*, 353-362.
- Yuda Kusuma, I., Octaviani, P., Oktavia, G. A., Fauqina, A. A., Pungki, J., Piri, A., & Kusuma, I. Y. (2021). Jurnal Farmasi Sains dan Praktis THE EFFECTS OF USING CLOZAPINE ON LEUKOCYTES, PLATELETS AND GLUCOSE LEVELS IN SCHIZOPHRENIC PATIENTS IN BANYUMAS HOSPITAL. In *JFSP* (Vol. 7, Issue 3). Desember. <http://journal.ummgl.ac.id/index.php/pharmacy>
- Yudhantara, D. S., & Istiqomah, R. (2018). Sinopsis Skizofrenia Untuk Mahasiswa Kedokteran, Malang.

- Yuen, J. W., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021). A focused review of the metabolic side-effects of clozapine. *Frontiers in Endocrinology*, *12*, 609240.
- Yulianty, M. D., Cahaya, N., & Srikartika, V. M. (2017). Studi penggunaan antipsikotik dan efek samping pada pasien skizofrenia di rumah sakit jiwa Sambang Lihum Kalimantan Selatan. *Jurnal Sains Farmasi & Klinis*, *3*(2), 153-164.
- Yunusa, I., & El Helou, M. L. (2020). The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. *Frontiers in Pharmacology*, *11*, 485120.
- Zahnia, S., & Sumekar, D. W. (2016). Kajian epidemiologis skizofrenia. *Jurnal Majority*, *5*(4), 160-166.
- Zapata, R. C., Silver, A., Yoon, D., Chaudry, B., Libster, A., McCarthy, M. J., & Osborn, O. (2022). Antipsychotic-induced weight gain and metabolic effects show diurnal dependence and are reversible with time restricted feeding. *Schizophrenia*, *8*(1), 70.
- Zhang, J. P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013). Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. *International Journal of Neuropsychopharmacology*, *16*(6), 1205-1218.
- Zhang, L., Yu, W. J., Zhu, H., Li, H. F., & Qiao, J. (2022). Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report. *World Journal of Clinical Cases*, *10*(21), 7495.
- Zhang, Y., Liu, Y., Su, Y., You, Y., Ma, Y., Yang, G., ... & Kou, C. (2017). The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. *BMC psychiatry*, *17*, 1-9